Asandeutertinib - Misplaced Pages

This is an old revision of this page, as edited by Boghog (talk | contribs) at 17:30, 30 December 2024 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 17:30, 30 December 2024 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound

Asandeutertinib
Clinical data

Other names	Runnor-9591, TY 9591
Identifiers
IUPAC name N--4-methoxy-5-pyrimidin-2-yl]amino]phenyl]prop-2-enamide
CAS Number	1638281-46-5
PubChem CID	87056175
IUPHAR/BPS	13201
UNII	9EKD2E8BM5
Chemical and physical data
Formula	C₂₈H₃₀D₃N₇O₂
Molar mass	502.636 g·mol
3D model (JSmol)	Interactive image
SMILES C()()N1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI InChI=InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i5D3 Key:DUYJMQONPNNFPI-VPYROQPTSA-N

Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties. Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.

References

^ "Asandeutertinib". PatSnap.
"Asandeutertinib". IUPHAR/BPS Guide to PHARMACOLOGY.
Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, et al. (October 2024). "P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation". Journal of Thoracic Oncology. 19 (10): S195. doi:10.1016/j.jtho.2024.09.353.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: